PRESERVE-C3Tx, a Phase 3b Pilot Study Design: Effect of Preemptive Pegcetacoplan Use on Recurrence of C3 Glomerulopathy or Primary Immune Complex-Membranoembranoproliferative Glomerulonephritis in Kidney Transplant Recipients (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO21-TH; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Exploratory endpoints will assess the impact of pegcetacoplan on disease activity markers (changes in proteinuria, eGFR, hematuria), renal biopsy features, graft outcomes (delayed graft function, graft rejection and failure events), complement biomarkers, as well as the impact of previous transplantations on the time to recurrence or graft failure. PRESERVE-C3Tx is expected to start recruitment by the end of 2026 with data to be presented over the coming years."
Clinical • P3 data • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Rare Diseases • Transplant Rejection • Transplantation
|
|
Dieter Haffner; Fernando Caravaca-Fontan; Moglie Le Quintrec; Marina Vivarelli; Diogo Buarque C. Cabral; Sheena Patel; Johan Szamosi; Neil S. Sheerin
|